<DOC>
	<DOC>NCT00150709</DOC>
	<brief_summary>The open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.</brief_summary>
	<brief_title>A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Have completed Study N151, or any other applicable pediatric trials of Levetiracetam (Keppra®) Be a patient for whom the treatment of Levetiracetam (Keppra®) would be of potential benefit such that the patient/parent(s)/legal guardian and the Investigator agree to continue treatment. Not be on a ketogenic diet (during the course of this study). Not have seizures too close together to accurately count (i.e., the patient's seizures must be countable).</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Epilepsy, Pediatric , partial onset epilepsy,</keyword>
	<keyword>Levetiracetam (Keppra®)</keyword>
</DOC>